Skip to content
10-K

Annual Report

DIAMEDICA THERAPEUTICS INC. DMAC

0001437749-25-008018

← back to feed
Filed
Mar 17, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 14, 2025 42.86M sh
Capex FY 2024 · Dec 31, 2023 $24K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$18.73M
Cash And Equivalents FY 2024 · Dec 31, 2023 $4.54M
Current Liabilities FY 2024 · Dec 31, 2023 $2.79M
Current Assets FY 2024 · Dec 31, 2023 $53.68M
Total Assets FY 2024 · Dec 31, 2023 $54.16M
Eps Basic FY 2024 · Dec 31, 2023 −$0.60
Sga Expense FY 2024 · Dec 31, 2023 $8.16M
Rd Expense FY 2024 · Dec 31, 2023 $13.11M
Net Income FY 2024 · Dec 31, 2023 −$19.38M
Operating Income FY 2024 · Dec 31, 2023 −$21.27M
Stockholders Equity FY 2024 · Dec 31, 2022 $31.83M